| Literature DB >> 34201125 |
Aline Yammine1, Amira Namsi1, Dominique Vervandier-Fasseur2, John J Mackrill3, Gérard Lizard1, Norbert Latruffe1.
Abstract
The Mediterranean diet is a central element of a healthy lifestyle, where polyphenols play a key role due to their anti-oxidant properties, and for some of them, as nutripharmacological compounds capable of preventing a number of diseases, including cancer. Due to the high prevalence of intestinal cancer (ranking second in causing morbidity and mortality), this review is focused on the beneficial effects of selected dietary phytophenols, largely present in Mediterranean cooking: apigenin, curcumin, epigallocatechin gallate, quercetin-rutine, and resveratrol. The role of the Mediterranean diet in the prevention of colorectal cancer and future perspectives are discussed in terms of food polyphenol content, the effectiveness, the plasma level, and the importance of other factors, such as the polyphenol metabolites and the influence of the microbiome. Perspectives are discussed in terms of microbiome-dependency of the brain-second brain axis. The emergence of polyphenol formulations may strengthen the efficiency of the Mediterranean diet in the prevention of cancer.Entities:
Keywords: EGCG; Mediterranean diet; apigenin; curcumin; dietary polyphenols; intestinal cancer; microbiota; polyphenol nanoformulation; quercetin; resveratrol; rutin
Mesh:
Substances:
Year: 2021 PMID: 34201125 PMCID: PMC8227701 DOI: 10.3390/molecules26123483
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Total polyphenols content of main edible plants from Mediterranean diet. Adapted from Debbabi et al. [2].
| Fruits | Mean of Total Polyphenol Content (mg of GAE/100g Fresh Edible Portion) | Vegetables | Mean of Total Polyphenol Content |
|---|---|---|---|
| Strawberry | 263.8 | Artichoke heart | 321.3 |
| Lychee | 222.3 | Parsley | 280.2 |
| Grape | 195.5 | Brussels sprout | 257.1 |
| Apricot | 179.8 | Shallot | 104.1 |
| Apple | 1179.1 | Broccoli | 98.9 |
| Date | 99.3 | Celery | 84.7 |
| Cherry | 94.3 | Onion | 79.1 |
| Fig | 92.5 | Eggplant | 65.6 |
| Pear | 69.2 | Garlic | 59.4 |
| White nectarine | 72.7 | Turnip | 54.7 |
| Passion fruit | 71.8 | Celeriac | 39.8 |
| Mango | 68.1 | Radish | 38.4 |
| Yellow/white peach | 59.3–44.2 | Pea | 36.7 |
| Banana | 51.5 | Leek | 32.7 |
| Pineapple | 47.2 | Red bell pepper | 26.8 |
| Lemon | 45 | Cherry tomato | 26.6 |
| Grape fruit | 43.5 | Potato | 23.1 |
| Orange | 31 | Zucchini | 18.8 |
| Clementine | 30.6 | Green bell pepper | 18.2 |
| Lime | 30.6 | Chicory | 14.7 |
| Kiwi | 28.1 | Asparagus | 14.5 |
| Watermelon | 11.6 | Tomato | 13.7 |
| melon | 7.8 | Fennel | 13 |
| Cauliflower | 12.5 | ||
| Carrot | 10.1 | ||
| French string bean | 10 | ||
| Avocado | 3.6 |
Fruit and vegetables with high polyphenols content characterized by important anti-oxidant activity. Adapted from Debbabi et al. [2].
| Extracts | Polyphenols Expressed in (mg/100 g of Fresh Matter) |
|---|---|
| Muscat grape | Gallic acid (1.7), epigallocatechin (10.8), catechin (21.8), epicatechin (5.3), quercetin-3- |
| White grape | Gallic acid (1.1), caftaric acid (10.8), epigallocatechin (4.4), catechin (10.6), epicatechin (6.0), quercetin-3- |
| Strawberry | Epigallocatechin (6.3), catechin (7.1), epicatechin (4.1), epicatechin gallate (1.3), quercetin-3- |
| Raspberry | Rutin (1.6), quercetin-3- |
| Beans | Catechin (1.0), myricetin-3- |
| Tomato | Chlorogenic acid (2.4), myricetin-3- |
| Celery | Chlorogenic acid (75.3), quercetin-3,4′-diglucoside (2.3), rutin (368.9), quercetin-3-beta-glucoside (5.7), kaempferol-3-rutinoside (22.1) |
| Radish | Catechin (2.7) |
Figure 1(A) Polyps as precancerous intestinal cancer, (B) colonic carcinogenesis stages. Adapted from the PhD Thesis of Dr F. Mazué (Director of Thesis; Prof. N. Latruffe; https://www.theses.fr/165862416, accessed on 7 June 2021).
Figure 2Chemical structures of selected polyphenols: 1: curcumin; 2: quercetin; 3: apigenin; 4: resveratrol; 5: Rutin; 6: EGCG.
Main characteristics of selected polyphenols.
| Polyphenol | Mol.Formula | Water Solubility (mg/L) | Main Dietary and Geographic Sources | Ref. |
|---|---|---|---|---|
| 1: Curcumin | C21H20O6 | 0.125 mg/L | Rhizomes of C | [ |
| 2: Quercetin | C15H10O7 | 0.48 mg/L | Red grape, onion, broccoli, tomato, lettuce | [ |
| 3: Apigenin | C15H10O5 | 1.43 mg/L | Chamomile (Europe, Western Asia) | [ |
| 4: Resveratrol | C14H12O3 | 30 mg/L | Grapes and red wine, | [ |
| 5: Rutin | C27H30O16 | 130 mg/L | Red grape, citrus, apple, fig, | [ |
| 6: EGCG | C22H18O11 | 5733.12 mg/L | Green tea from leaves and buds of | [ |
Figure 3Metabolism of resveratrol. Adapted from Delmas et al., [47]. ER: estrogen-receptor; ABP: albumin-binding protein; LDL: low density lipoprotein; LDL-R: low density lipoprotein-receptor. resveratrol; glucurono resveratrol; sulfo resveratrol.
Figure 4Contribution of the gut microbiota to polyphenol metabolism. The metabolites of polyphenols (curcumin, quercetin, apigenin, resveratrol, rutin and EGCG) produced by the gut microbiota are written in blue.
Antitumoral effects of apigenin in colorectal cancer.
| APIGENIN | ||||
|---|---|---|---|---|
| Experimental | Concentration Range | Biological Response | Pathway/Genes/Proteins Involved | Refs. |
| Cells and Cell Lines | ||||
| HCT-15 | 43.28 µM | ↑ Cell cytotoxicity | ↑ p21, ↑ cyclin B1 | [ |
| SW480 | 40 µM | ↓ Proliferation | ↓ Wnt/β-catenin | [ |
| ↓ Cell migration, ↓ Invasion, ↓ Metastasis | ↓ FAK, Src, crk-L, AKT | [ | ||
| ↓ Proliferation | ↓ NEDD9 | |||
| HCT-116 | 25 µM | ↓ Proliferation, ↓ Apoptosis ↓ Autophagy | ↓ Cyclin B1, ↓Cdc2, Cdc25c, | [ |
| 20 μM and | ↑ Autophagy/Apoptosis ↓ Cell grouth, cell cycle arrest G2/M | ↓ PI3K/AKT/Mtor | [ | |
| 10 µM | ↑ Apoptosis, ↓ Trascriptional level | PKCδ/ATM kinase, ↓ NAG-1, | [ | |
| LoVo | 1–10 µM | ↑ Apoptosis | ↓ NAG-1, ↓ p53, ↓ p21 | |
| DLD-1 | 40 µM | ↓ Cell migration, ↓ Invasion, ↓ Migration | ↓ NEDD9, ↓ FAK, Src, crk-L, AKT, ↑ TAGLN, ↓ MMP-9 | [ |
| ↓ Cell migration, ↓ Invasion, | ↑ TAGLN, ↓ MMP-9 | [ | ||
| HT-29 | 45.96 µM | ↑ cell cytotoxicity | ↑ p21, ↑ cyclin B1 | [ |
| Animal models | ||||
| Athymic nude mice | 20 mg/kg | ↓ Cell migration, ↓ Invasio | ↓ FAK, Src, crk-L, AKT | [ |
| ↓ NEDD9 | ||||
| 50 mg/kg (I.P) | ↓ Angigenesis | ↓ CD-31, ↓ Ki-67 | [ | |
| BALB/c-nude mice | 50 mg/kg | ↓ Cell migration, ↓ Invasion, ↓ Proliferation | ↑ TAGLN, ↓ MMP-9 | [ |
| APCMin/+ mice | 50 mg/kg (I.P) | ↓ tumor volume, ↑ Apoptosis | ↑ p21, ↓ p53 | [ |
Antitumoral effects of curcumin in colorectal cancer.
| Curcumin | ||||
|---|---|---|---|---|
| Experimental | Concentration Range | Biological Response | Pathway/Genes/Proteins Involved | Refs. |
| Cells and Cell Lines | ||||
| HCT-116 | 10–25 µM | ↑ Apoptosis | ↓ AP-1, ↓ NF-κB, | [ |
| 20 µM with | ↑ Cell cycle arrest (S) | ↓ caspase-3, ↓ caspase-8, ↓ caspase-9, Bax, ↓ PARP, ↑ Bcl-2 | [ | |
| ↓ cyclin D1 | ||||
| 25 µM with Piperine (7 µM) | ↓ Cell proliferation | ↓ cyclin D1, ↑ caspase-3 | [ | |
| HT29 | 41 µM | ↓ Oxydative stress | ↓ NF-E2, ↓ Nrf2 | [ |
| HCT-8/5-Fu | 10 µM with | ↑ Apoptosis, | ↑ Nrf2, ↑ Bcl-2, ↓ Bax | [ |
| Animal models | ||||
| C57BL/6 | 300 mg/kg with DSS (5 mg/kg) I.P. | ↓ Disease activity index, | ↓ β-catenin, Cox2, iNOS | [ |
| ↑ Apoptotosis | ↓ cyclinD1, ↓ cyclinD3, ↑ caspase-3, ↑ caspase-7, | [ | ||
| Oxaliplatin-resistant | (1 g/kg) per os | ↑ Radiosensitivity | ↓ NF-κB, ↓ Ki-67, | [ |
| Orthopically implanted CRC tumors (HC116) | (1 g/kg) per os | ↓ Cell growth, | ↓ NF-κB | [ |
Antitumoral effects of EGCG in colorectal cancer.
| EGCG | ||||
|---|---|---|---|---|
| Experimental Models | Concentration Range | Biological Response | Pathway/Genes/Proteins Involved | Refs. |
| Cells and Cell Lines | ||||
| SW837 | 50–100 µM | ↓ Cell growth | ↑ IFN-γ, ↓ IDO, | [ |
| 10 ng/mL | ↓ Cell proliferation, | ↑ CD133, CD44, ALDHA1, | [ | |
| 10–30 µM | ↓ Cell growth, | ↓ MMP2/9, | [ | |
| 35 µg/mL | ↑ Cell cycle arrest (G0/G1) | [ | ||
| LoVo | 35 µg/mL | ↓ Cell proliferation, | [ | |
| 10–30 µM | ↓ Cell growth, | ↓ MMP2 and 9, | [ | |
| HT29 | 35 µg/mL | ↑ Cell cycle arrest (S) | [ | |
| 88 μM | ↑ ER stress, | ↑ Bip | [ | |
| 100 µM (with 20 µM csplatin | ↓ Cell viability, | ↑ LC3II, ↓ IP3K | [ | |
| HCT-8 | 35 µg/mL | ↑ Cell cycle arrest G2/M | [ | |
| HCT116 | 12.5 µM | ↑ Radiosensitivity, | ↑ Nrf2, ↑ LC3, | [ |
| 50–100 µM | ↓ Cell proliferation | [ | ||
| 50–100 µM | ↑ Apoptosis | ↓ VEGFR2, ↓ AKT, | [ | |
| 10–30 µM | ↓ Cell growth, | ↓ MMP2 and 9, | [ | |
| DLD-1, | 100 µM with (20 µM cisplatin | ↓ Cell viability, | ↑ LC3II, ↓ IP3K | [ |
| 10 ng/mL | ↓ Cell proliferation, | ↑ CD133, CD44, ALDHA1, | [ | |
| RKO | 50–100 µM | ↑ Apoptosis | ↑ p38 | [ |
| Caco-2 | 10–30 µM | ↓ Cell growth, | ↓ MMP2 and 9, ↑ caspases 3, 8 and 9, ↓ EGFR and IGF1R, ↓ MEK and ERK, | [ |
| Animal Models | ||||
| Male ICR mice | 0.1% with (AOM 10 mg/kg body weight I.P followed by 2% ( | ↓ Weight, | ↓ COX2, ↓ mRNA | [ |
| Eighty SPF Wistar rats | 200 mg/kg with (DMH 40 mg/kg, s.c) | ↓ Tumor volume, | ↓ p53, PI3K-Akt, | [ |
Antitumoral effects of quercetin in colorectal cancer.
| QUERCETIN | ||||
|---|---|---|---|---|
| Experimental | Concentration Range | Biological Response | Pathway/Genes/Proteins | Refs. |
| Cells and cell lines | ||||
| HT-29 | 25, 50, 100 µM | Apoptosis | ↓ Bcl-2, ↑ cleaved caspase-3, ↑ cleaved PARP, ↓ p-Akt, ↓ ErbB2/ErbB3 proteins | [ |
| 5–30 µg/mL (with resveratrol, | ↓ Oncogenic | ↓ Sp1, ↓ Sp3, ↓ Sp4, | [ | |
| 50, 100, 200 µM | Apoptosis | ↓ p-Akt, ↓ CSN6, ↓ Myc, ↓ Bcl-2, ↑ p53, ↑ Bax proteins | [ | |
| 50 μM (with cisplatin: 10 mg/L) | ↑ Cisplatin-induced Apoptosis | ↓ Activation of NF-κB protein expression | [ | |
| 30 µM | ↑ TRAIL-induced Apoptosis | Redistribution of death receptors DR4 and DR5 into lipid rafts | [ | |
| 50, 100 μM | Apoptosis | ↑ AMPK, ↑ p53, ↑ p21 proteins | [ | |
| 50 µM | ↑ Doxorubicin-induced cytotoxicity | ↓ Proliferation, ↑ apoptosis, and G2/M arrest for lower IC50 of Dox | [ | |
| Caco-2 | 5–50 µM | ↓ Cell proliferation | ↓ CDC6, ↓ CDK4, ↓ cyclin D1 mRNA | [ |
| 5–20 μM | Anti-migration | ↓ MMP-2, ↓ MMP-9, ↓ TLR4, ↓ NF-κB, ↑ E-cadherin proteins | [ | |
| Caco-2 | 25–100 µM | Apoptosis | ↑ IκB-α, ↓ p-IκB-α, ↓ Bcl-2, | [ |
| SW480 | 20–80 µM | Apoptosis | ↓ Cyclin D1, ↓ survivin mRNA, and proteins | [ |
| 10 µM | Apoptosis | ↓ EGF receptor phosphorylation | [ | |
| Colo-320 | 25 μg/mL | Apoptosis Senescence | ↑ p16, ↑ Lamin B1, ↑ cyclin B1, ↑ Bax, ↓ Bcl-2 proteins | [ |
| CT26 | 1–10 µM | Anti-metastasis | ↑ E-cadherin, ↓ N-cadherin, | [ |
| DLD-1 | 10.5 µM | Anticarcinogenesis | ↓ COX-2 transcription | [ |
| CO115 | 12 µM | ↑ Fluorouracil-induced apoptosis | ↑ p53, ↑ cleaved caspase-9, | [ |
| HCT8-β8 | 50 µM | ↓ Cell proliferation | ↑ ERβ mRNA, ↑ ER-responsive luciferase activity | [ |
| Animal models | ||||
| HT-29 xenograft in Balb/C nude mice | 10 mg/kg/day | ↑ Radiosensitivity | ↓ Jagged-1, ↓ Notch-1, ↓ Hes-1, | [ |
Antitumoral effects of rutin in colorectal cancer.
| RUTIN | ||||
|---|---|---|---|---|
| Experimental | Concentration Range | Biological Response | Pathway/Genes/Proteins | Refs. |
| Cells and cell lines | ||||
| HT-29 | 100–200 µM | Apoptosis | ↑ Bax, ↓ Bcl-2, ↑ cleaved caspases-3, 8, 9, ↑ cleaved PARP proteins | [ |
| 39 mM (with Silibinin: 76 mM) | Apoptosis | ↑ p53, ↓ Bcl-2, ↑ Bax, ↑ caspase 3, 8, 9 | [ | |
| HT-29 | 25–200 µM | ↓ Cell adhesion and Migration | ↓ ROS level, impairing attachment to fibronectin, disrupting cell–ECM interactions | [ |
| 136 µM | ↓ Cell proliferation | ↓ Growth potency | [ | |
| Animal models | ||||
| SW480 xenograft in nude mice | 1–20 mg/kg/day (I.P; 32 days) | Anti-tumor | ↑ Mean survival time, ↓ tumor volume, and weight, ↓ VEGF levels in serum | [ |
| MTX-treated Wistar rats (Intestinal inflammation) | 50, 100 mg/kg/day (I.P; 1 week) | ↓ Oxidative stress | ↓ COX-1, ↓ COX-2, and ↓ 15 LOX enzymatic activities, restoration of MDA, protein carbonyl, SOD, GSH levels, and catalase activity, ↓ free acidity and total acidity | [ |
| 5-FU-treated Swiss mice (Intestinal Mucositis) | 50–200 mg/kg/day (Per os; 3 days) | ↓ Oxidative stress | ↓ MDA, ↑ GSH concentrations, | [ |
| DSS-treated ICR mice (Colitis) | 0.6–6 mg/day (Per os; 2 weeks) | ↓ Inflammation | ↓ IL-1β, ↓ IL-6, ↓ GM-CSF, ↓ iNOS mRNA | [ |
Figure 5Chemical structures of co-encapsulated compounds: alantolactone (7), chrysin (8), piperine (9).